Kutumiza kwachitetezo CAS 1156491-10-9 (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride Ubwino Wabwino Wotsika Mtengo Wabwino Kwambiri Mtengo Wotsikitsitsa

Ticagrelor ndi mankhwala a antiplatelet oral, dzina lake la American brand Brilinta, ndipo dzina lake la ku Ulaya ndi Brilique. Ticagrelor ndi reversible platelet adenosine diphosphate (ADP) receptor antagonist yopangidwa kuti ateteze mapulateleti kuti asagwirizane ndi kupanga magazi omwe angayambitse matenda a mtima ndi zikwapu. Ku United States, ticagrelor inayamba kuvomerezedwa ndi FDA mu July 2011 pofuna kuchiza odwala akuluakulu omwe ali ndi matenda aakulu (ACS). Deta yachipatala imasonyeza kuti ticagrelor ndi yothandiza kwambiri kuposa clopidogrel pochepetsa imfa ya mtima kwa miyezi yosachepera 12 pambuyo pa chochitika cha ACS. Kuonjezera apo, ticagrelorChemicalbook inachepetsanso chiwerengero cha stent thrombosis (ST) kwa odwala omwe adalandira stents kuti athetse ACS. Mu June 2020, AstraZeneca adalengeza kuti US Food and Drug Administration (FDA) idavomereza anticoagulant Brilinta (ticagrelor) kuti igwiritsidwe ntchito kwa odwala omwe ali ndi chiopsezo chachikulu cha matenda a mtima (CAD) kuti achepetse chiopsezo cha matenda a mtima woyamba. kapena chiopsezo cha sitiroko. Mu Novembala 2020, AstraZeneca idalengeza kuti US Food and Drug Administration (FDA) idavomereza chiwonetsero chatsopano cha anticoagulant Brilinta (ticagrelor), kuphatikiza aspirin, pochiza ischemia pachimake. Odwala omwe ali ndi matenda a hemorrhagic stroke kapena omwe ali pachiwopsezo chachikulu cha ischemic (TIA), amachepetsa chiopsezo cha sitiroko.